Drug Trial Radar · NCT01784536
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jan 2013
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- Melinta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
Conditions
- Healthy
Interventions
Single-Dose IV Oritavancin DiphosphateDrug
Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the phenotyping measures of each probe drug in the absence and presence of oritavancinTime frame: Day 1 through Day 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spaulding Clinical
West Bend, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.